PL2470671T3 - Przeciwciała antykinowe wiążące się z wieloma chemokinami CC - Google Patents

Przeciwciała antykinowe wiążące się z wieloma chemokinami CC

Info

Publication number
PL2470671T3
PL2470671T3 PL10812667T PL10812667T PL2470671T3 PL 2470671 T3 PL2470671 T3 PL 2470671T3 PL 10812667 T PL10812667 T PL 10812667T PL 10812667 T PL10812667 T PL 10812667T PL 2470671 T3 PL2470671 T3 PL 2470671T3
Authority
PL
Poland
Prior art keywords
chemokines
bind
antikine antibodies
antikine
antibodies
Prior art date
Application number
PL10812667T
Other languages
English (en)
Inventor
Dan Allison
Carol Raport
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL2470671T3 publication Critical patent/PL2470671T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10812667T 2009-08-28 2010-08-27 Przeciwciała antykinowe wiążące się z wieloma chemokinami CC PL2470671T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23801509P 2009-08-28 2009-08-28
EP20100812667 EP2470671B1 (en) 2009-08-28 2010-08-27 Antikine antibodies that bind to multiple cc chemokines
PCT/US2010/047004 WO2011025962A1 (en) 2009-08-28 2010-08-27 Antikine antibodies that bind to multiple cc chemokines

Publications (1)

Publication Number Publication Date
PL2470671T3 true PL2470671T3 (pl) 2015-05-29

Family

ID=43628404

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10812667T PL2470671T3 (pl) 2009-08-28 2010-08-27 Przeciwciała antykinowe wiążące się z wieloma chemokinami CC

Country Status (18)

Country Link
US (3) US8313747B2 (pl)
EP (1) EP2470671B1 (pl)
JP (2) JP6109571B2 (pl)
KR (1) KR101778813B1 (pl)
CN (1) CN102782148B (pl)
AU (1) AU2010286516B2 (pl)
BR (1) BR112012004387A2 (pl)
CA (1) CA2771781C (pl)
DK (1) DK2470671T3 (pl)
ES (1) ES2531561T3 (pl)
HR (1) HRP20150162T1 (pl)
IN (1) IN2012DN01769A (pl)
MX (1) MX2012002427A (pl)
PL (1) PL2470671T3 (pl)
PT (1) PT2470671E (pl)
SI (1) SI2470671T1 (pl)
SM (1) SMT201500011B (pl)
WO (1) WO2011025962A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150162T1 (hr) * 2009-08-28 2015-05-08 Regeneron Pharmaceuticals, Inc. Antikin antitijela koja se vežu na višestruke cc kemokine
EP2717941B1 (en) * 2011-06-13 2020-04-01 TLA Targeted Immunotherapies AB Treating cancer
WO2013033206A2 (en) * 2011-08-29 2013-03-07 University Of Rochester Compositions and methods for inhibiting ccl3
WO2013036290A1 (en) * 2011-09-09 2013-03-14 Yale University Compositions and methods for assessing and treating inflammatory diseases and disorders
KR102134088B1 (ko) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
JO3580B1 (ar) * 2013-03-15 2020-07-05 Lilly Co Eli أجسام مضادة لكيموكين elr+ cxc شامل
HK1224174A1 (zh) 2013-05-23 2017-08-18 Takeda Pharmaceutical Company Limited 用於治疗硬皮病的抗ccl2 和抗loxl2 组合疗法
JP6220222B2 (ja) * 2013-10-28 2017-10-25 シスメックス株式会社 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品
HRP20192052T1 (hr) * 2013-12-09 2020-02-07 Allakos Inc. Protutijela anti-siglec-8 te njihovi postupci i uporabe
US10183996B2 (en) 2014-02-28 2019-01-22 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases
BR112016020366B1 (pt) 2014-03-04 2024-01-02 Chemomab Ltd Anticorpo isolado que se liga a uma quimiocina de ligação a ccr3, molécula de ácido nucleico, vetor de expressão, célula hospedeira microbiana, e composição farmacêutica
CN104198727A (zh) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
TWI576112B (zh) * 2014-10-24 2017-04-01 國立陽明大學 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用以保護胰臟及防止血糖升高的用途
CN107257624B (zh) 2014-12-09 2021-07-13 瑞泽恩制药公司 具有人源化分化簇274基因的非人动物
JP6846362B2 (ja) 2015-06-17 2021-03-24 アラコス インコーポレイテッド 線維性疾患を処置するための方法および組成物
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
JP7122002B2 (ja) 2017-03-01 2022-08-19 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
MX2019011958A (es) * 2017-04-05 2019-12-11 Korea Res Inst Bioscience & Biotechnology Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye.
AU2018261887A1 (en) 2017-05-05 2019-12-05 Allakos Inc. Methods and compositions for treating allergic ocular diseases
WO2019037067A1 (zh) * 2017-08-25 2019-02-28 法玛科技顾问股份有限公司 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途
WO2019075472A1 (en) * 2017-10-13 2019-04-18 A&G Pharmaceutical, Inc. MONOCLONAL AND CONJUGATED ANTIBODIES AGAINST THE PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF
EP3732196A4 (en) * 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND ASSAYS FOR CCL14
WO2019165397A1 (en) * 2018-02-26 2019-08-29 Cornell University Quantitative biomarkers of ehv-1 susceptibility and protection
EP3791187A4 (en) * 2018-05-11 2022-01-12 Halcyon Therapeutics, Inc. BINDING PROTEINS AND CHIMERIC ANTIGEN RECEPTOR T-CELLS AGAINST GASP-1 GRANULES AND THEIR USE
US20240252795A1 (en) 2018-11-19 2024-08-01 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN110117329B (zh) * 2019-04-03 2020-12-08 河北浓孚雨生物科技有限公司 包含趋化因子与结合伴侣的融合多肽及其用途
KR102489282B1 (ko) * 2019-07-02 2023-01-17 고려대학교 산학협력단 Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물
CN114341178B (zh) * 2019-07-02 2024-05-07 机敏医药股份有限公司 Ccl14的抗体和检测
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN113893331B (zh) * 2020-07-06 2024-11-26 中国农业科学院特产研究所 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用
EP4178614A4 (en) * 2020-07-08 2024-10-30 Georgia Tech Research Corporation COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF SARS-COV-2 VIRUS INFECTIONS
AU2021277712B2 (en) 2020-10-16 2023-05-25 LaNova Medicines Limited Anti-CCR8 monoclonal antibodies and uses thereof
CN115598111B (zh) * 2021-07-08 2025-03-25 南京大学 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法
CN114990073A (zh) * 2022-05-27 2022-09-02 河南农业大学 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
EP1542724A4 (en) 2002-08-19 2005-10-19 Abgenix Inc ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF
AU2003293096B9 (en) 2002-11-27 2011-09-29 Biogen Ma Inc. Humanized antibodies against monocyte chemotactic proteins
CA2590446A1 (en) 2004-12-21 2006-06-29 Laboratoires Serono S.A. Cc-chemokine antagonists
CA2695237A1 (en) * 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
HRP20150162T1 (hr) * 2009-08-28 2015-05-08 Regeneron Pharmaceuticals, Inc. Antikin antitijela koja se vežu na višestruke cc kemokine

Also Published As

Publication number Publication date
CA2771781C (en) 2019-01-15
CN102782148B (zh) 2016-04-20
JP2016135783A (ja) 2016-07-28
AU2010286516A1 (en) 2012-03-08
EP2470671A1 (en) 2012-07-04
JP2013503192A (ja) 2013-01-31
WO2011025962A1 (en) 2011-03-03
KR101778813B1 (ko) 2017-09-14
US8313747B2 (en) 2012-11-20
JP6109571B2 (ja) 2017-04-05
MX2012002427A (es) 2012-08-03
SMT201500011B (it) 2015-03-05
BR112012004387A2 (pt) 2015-09-08
US9005617B2 (en) 2015-04-14
HRP20150162T1 (hr) 2015-05-08
DK2470671T3 (en) 2015-02-09
AU2010286516B2 (en) 2016-10-06
KR20120091013A (ko) 2012-08-17
RU2012111820A (ru) 2013-10-10
CN102782148A (zh) 2012-11-14
PT2470671E (pt) 2015-02-05
CA2771781A1 (en) 2011-03-03
ES2531561T3 (es) 2015-03-17
IN2012DN01769A (pl) 2015-06-05
US20150166647A1 (en) 2015-06-18
AU2010286516A2 (en) 2012-06-14
US20110059107A1 (en) 2011-03-10
SI2470671T1 (sl) 2015-04-30
EP2470671A4 (en) 2013-04-03
US20130108640A1 (en) 2013-05-02
EP2470671B1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
PT2470671E (pt) Anticorpos anticinas que se ligam a múltiplas quimiocinas
IL257712B (en) Antibodies that bind csf1r
IL215696A0 (en) Antibodies specific to cadherin-17
ZA201202329B (en) Antibodies that specifically bind to the epha2 receptor
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
SG10201401331TA (en) Anti-siglec-15 antibody
GB0909906D0 (en) Antibodies
HUE040213T2 (hu) Anti-TIM antitest
LT3342786T (lt) Anti-dll3 antikūnai
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
GB0920324D0 (en) Antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB2473934B (en) Anti-VEEV antibody
GB201007957D0 (en) Antibody
GB0911712D0 (en) Antibody
GB0908945D0 (en) Antibodies
GB201017780D0 (en) Antibody